Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies

Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IB...

Descripción completa

Detalles Bibliográficos
Autores principales: Boland, Brigid S., Goodwin, Benjamin, Zhang, Zeli, Bloom, Nathaniel, Kato, Yu, Neill, Jennifer, Le, Helen, Tysl, Tiffani, Collins, Angelina E., Dulai, Parambir S., Singh, Siddharth, Nguyen, Nghia H., Grifoni, Alba, Sette, Alessandro, Weiskopf, Daniela, Chang, John T., Dan, Jennifer M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9038482/
https://www.ncbi.nlm.nih.gov/pubmed/35347100
http://dx.doi.org/10.14309/ctg.0000000000000484
Descripción
Sumario:Immune-modulating medications for inflammatory bowel diseases (IBDs) have been associated with suboptimal vaccine responses. There are conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks after second mRNA vaccination in 29 patients with IBD compared with 12 normal healthy donors. We observed reduced humoral immunity in patients with IBD on infliximab. However, we observed no difference in humoral and cell-mediated immunity in patients with IBD on infliximab with a thiopurine or vedolizumab compared with normal healthy donors. This is the first study to demonstrate comparable cell-mediated immunity with SARS-CoV-2 vaccination in patients with IBD treated with different immune-modulating medications.

Ejemplares similares